Literature DB >> 19958926

One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?

Alexander L Shifrin1, Cristina Xenachis, Angela Fay, Theodore J Matulewicz, Yen-Hong Kuo, Jerome J Vernick.   

Abstract

BACKGROUND: The rearranged during transfection (RET) V804M proto-oncogene mutation is rare and associated with medullary thyroid carcinoma (MTC). We present 40 members from a total cohort of 107 family members with this mutation.
METHODS: Family members were tested for RET mutations, calcitonin levels, and screened for pheochromocytoma and primary hyperparathyroidism (PHPT). Thyroidectomies were performed on 15 members. Surgery and pathology reports were obtained and reviewed. A pedigree was constructed.
RESULTS: A high penetrance was found for MTC and simultaneous papillary thyroid carcinoma (PTC; 40%). The incidence of PHPT was low (13%). There were no findings of pheochromocytoma. The course in the first family generation was indolent, with late onset of MTC. The second generation experienced earlier disease development; onset occurred earliest in the third generation. The second generation experienced a higher incidence of PTC than the first.
CONCLUSION: This is the largest family with this mutation reported to date. However, it does not fit the classic familial MTC or MEN 2A cancer syndrome. Considering that PTC is not an incidental finding, but the result of an inherited RET V804 M mutation, we propose to identify this phenotypic expression as a unique syndrome consistent with manifestations of MTC, PHPT, and PTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958926     DOI: 10.1016/j.surg.2009.09.021

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  Papillary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  B Febrero; J M Rodríguez; A Ríos; P Portillo; P Parrilla
Journal:  J Endocrinol Invest       Date:  2015-04-23       Impact factor: 4.256

2.  Case of Concurrent MTC and PTC in a Patient with a Germline RET Mutation.

Authors:  Kinjal Shah; Mohsen Zena; Edward D Adickes; Robert J Anderson
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

3.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

4.  Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Authors:  R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei
Journal:  J Endocrinol Invest       Date:  2016-08-17       Impact factor: 4.256

5.  Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.

Authors:  M N Basaran; M M Tuna; E Karakılıç; B A Doğan; N N İmga; D Berker; S Güler
Journal:  J Endocrinol Invest       Date:  2014-12-12       Impact factor: 4.256

Review 6.  Controversy on the management of patients carrying RET p.V804M mutation.

Authors:  Ali S Alzahrani; Meshael Alswailem; Balgees Alghamdi; Rafiullah Rafiullah; Mohammed Aldawish; Hindi Al-Hindi
Journal:  Endocrine       Date:  2021-10-12       Impact factor: 3.633

7.  How to Assess the Clinical Relevance of Novel RET Missense Variants in the Absence of Functional Studies?

Authors:  Thomas Karrasch; Saskia M Herbst; Ute Hehr; Andreas Schmid; Andreas Schäffler
Journal:  Eur Thyroid J       Date:  2016-02-25

8.  Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.

Authors:  Katerina Saltiki; Elli Anagnostou; George Simeakis; Sofia Kouki; Anastasia Angelopoulou; Leda Sarika; Alexandra Papathoma; Maria Alevizaki
Journal:  Endocr Connect       Date:  2017-09-26       Impact factor: 3.335

9.  A Case of medullary thyroid carcinoma with de novo V804M RET germline mutation.

Authors:  Young Sik Choi; Hye Jung Kwon; Bu Kyung Kim; Su Kyoung Kwon; Yo Han Park; Jeong Hoon Kim; Sang Bong Jung; Chang Hoon Lee; Seong Keun Lee; Shinya Uchino
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

10.  Positive Germline Selection in Pedigrees With Multiple Endocrine Neoplasia Type 2 Carrying V804M Mutation in the RET Gene.

Authors:  Leema Reddy Peddareddygari; Angela Musial Fay; Alexander L Shifrin; Raji P Grewal
Journal:  World J Oncol       Date:  2016-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.